SLC31A1 and osteosarcoma: reported that, in cisplatin-resistant osteosarcoma, the RNA-binding protein PTBP1 accelerated the SLC31A1 mRNA degradation by directly binding to it, which downregulated the SLC31A1 protein level and reduced the cell’s sensitivity to cisplatin [247].